ASTRAZEN vs CAPLIPOINT: Stock Comparison
CAPLIN POINT LAB is the larger company by market capitalisation. ASTRAZENECA PHARMA IND LT shows a higher ROE, a higher dividend yield and faster revenue growth, while CAPLIN POINT LAB shows a lower P/E and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ASTRAZEN leads 4; CAPLIPOINT leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ASTRAZEN | CAPLIPOINT |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ASTRAZEN | CAPLIPOINT |
|---|---|---|
| Live Price | ₹6,944 | ₹2,810.8 |
| Day Change | 0.05% | -1.2% |
| Volume | 6,489 | 2.09 L |
| 52-Week High | ₹9,849.5 | ₹2,877.3 |
| 52-Week Low | ₹6,835 | ₹1,500.3 |
| Distance from 52W High | -29.5% | -2.31% |
Valuation
| Metric | ASTRAZEN | CAPLIPOINT |
|---|---|---|
| Market Cap | ₹17,288 Cr | ₹21,207 Cr |
| P/E Ratio | 101.61x | 31.23x |
| P/B Ratio | 19.75x | 5.79x |
| EPS | ₹15.17 | ₹23.27 |
| Book Value | ₹349.12 | ₹477.66 |
| Dividend Yield | 0.52% | 0.25% |
Growth
| Metric | ASTRAZEN | CAPLIPOINT |
|---|---|---|
| Revenue Growth (TTM YoY) | 20.4% | 19% |
| EPS Growth (TTM YoY) | -23% | 19.4% |
| Qtr Sales Growth | -69.99% | 200.74% |
| Qtr Profit Growth | -79.77% | 48.77% |
Profitability & Leverage
| Metric | ASTRAZEN | CAPLIPOINT |
|---|---|---|
| ROE | 21.49% | 18.79% |
| ROCE | 44.9% | 19.67% |
| Net Margin | 8.24% | 29.2% |
| Operating Margin | 11.28% | 67.23% |
| Debt to Equity | 0x | 0x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | ASTRAZEN | CAPLIPOINT |
|---|---|---|
| Promoter Holding | 0% | 70.57% |
| FII Holding | 2.68%▼ 0.1 pp | 5.75%▼ 0.4 pp |
| DII Holding | 6.08%▲ 0.28 pp | 2.49%▲ 0.35 pp |
| Public Holding | 16.24%▼ 0.18 pp | 21.18%▲ 0.04 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ASTRAZENECA PHARMA IND LT and CAPLIN POINT LAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.